SCHEMBL29816632

SCHEMBL29816632

O=C(O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 4/20 0.44
▸ DPP8 Q6V1X1 3/20 0.44
▸ DPP9 Q86TI2 3/20 0.44
▸ CHRM3 P20309 12/20 0.44
▸ CHRM2 P08172 10/20 0.44
▸ CHRM4 P08173 9/20 0.44
▸ CHRM1 P11229 8/20 0.42
▸ CHRM5 P08912 6/20 0.41
▸ FAP Q12884 1/20 0.39
▸ DPP7 Q9UHL4 1/20 0.39
▸ PREP P48147 1/20 0.36
▸ VHL P40337 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29504152 1.00 DPP4 (0.44) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL29816367 1.00 DPP4 (0.44) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL29728563 0.92 CHRM2 (0.49) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL29411118 0.90 DPP4 (0.53) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL12135710 0.90 DPP4 (0.53) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL29411145 0.89 DPP4 (0.44) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL31497255 0.89 DPP4 (0.44) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL29816377 0.89 DPP4 (0.44) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL30785833 0.89 BDKRB2 (0.38) DPP4DPP8DPP9CHRM3CHRM2
SCHEMBL31135206 0.88 CHRM2 (0.49) DPP4DPP8DPP9CHRM3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115261-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF SUSTAIN HOLDINGS LLC (US) 2026-04-30 — — US disclosed
US-12551525-B2 Collagen peptide-based medicament compositions and devices and methods of production and use thereof SUSTAIN HOLDINGS, LLC (US) 2026-02-17 — — US disclosed
US-12419936-B2 Collagen peptide-based medicament compositions and devices and methods of production and use thereof SUSTAIN HOLDINGS, LLC (US) 2025-09-23 — — US disclosed
US-20250268974-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF SUSTAIN HOLDINGS, LLC 2025-08-28 — — US disclosed
US-20250213641-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF SUSTAIN HOLDINGS, LLC 2025-07-03 — — US disclosed
EP-4552693-A2 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF Sustain Holdings, LLC (US) 2025-05-14 — — EP disclosed
US-12280086-B2 Collagen peptide-based medicament compositions and devices and methods of production and use thereof SUSTAIN HOLDINGS, LLC (US) 2025-04-22 — — US disclosed
EP-3958889-B1 COLLAGEN MIMETIC PEPTIDE COMPOSITIONS FOR TREATING A POSTERIOR SEGMENT OCULAR DISEASE OR DISORDER INVOLVING THE RETINA, RETINAL BLOOD VESSELS, RETINAL NERVES OR OPTIC NERVE SUSTAIN HOLDINGS LLC (US) 2025-01-08 — — EP disclosed
EP-4477267-A2 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS FOR USE IN THE TREATMENT OF OCULAR DISEASES, DISORDERS OR WOUNDS Sustain Holdings, LLC (US) 2024-12-18 — — EP disclosed
US-20240100118-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF SUSTAIN HOLDINGS, LLC 2024-03-28 — — US disclosed
US-20240016900-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF SUSTAIN HOLDINGS, LLC 2024-01-18 — — US disclosed
US-20230338458-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF SUSTAIN HOLDINGS, LLC 2023-10-26 — — US disclosed
US-11684651-B2 Collagen peptide-based medicament compositions and devices and methods of production and use thereof SUSTAIN HOLDINGS, LLC (US) 2023-06-27 — — US disclosed
US-20230141917-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF SUSTAIN HOLDINGS, LLC 2023-05-11 — — US disclosed
US-20230048200-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF SUSTAIN HOLDINGS, LLC 2023-02-16 — — US disclosed
US-20220280592-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF SUSTAIN HOLDINGS LLC (US) 2022-09-08 — — US disclosed
US-11433112-B1 Collagen peptide-based medicament compositions and devices and methods of production and use thereof SUSTAIN HOLDINGS, LLC (US) 2022-09-06 — — US disclosed
US-11426440-B2 Collagen peptide-based medicament compositions and devices and methods of production and use thereof SUSTAIN HOLDINGS, LLC (US) 2022-08-30 — — US disclosed
US-11389513-B2 Collagen peptide-based medicament compositions and devices and methods of production and use thereof SUSTAIN HOLDINGS, LLC (US) 2022-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115261-A1 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF COL1A1, COL2A1, COL14A1 DPP4 852/4885DPP8 2138/4885DPP9 1537/4885
US-12551525-B2 Collagen peptide-based medicament compositions and devices and methods of production and use thereof COL2A1, COL14A1, COL1A1 DPP4 1566/4885DPP8 2253/4885DPP9 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback